Abstract: Coronary heart disease (CHD) is the main cause of cardiovascular death. Identifying blood-based biomarkers to provide prognostic value and significant re-classification ability is of great help to risk stratification and proper management of coronary heart disease. Vascular inflammation is an important part of the pathophysiological pathway of coronary heart disease. More and more clinical evidence shows that amyloid β (aβ), as a peptide with pro-inflammatory and pro thrombogenic properties, plays an important role in the progression of atherosclerotic plaque. In this review, we summarize the research progress of amyloid β in coronary heart disease, which may provide important theoretical basis and guiding value for new anti-inflammatory treatment targets of coronary heart disease patients.